Baxalta Partners with Novimmune SA on Bispecific Antibody Research
The collaborative effort will be focused on fully humanized antibodies.
Novimmune SA and Baxalta announced on Sept. 2, 2015 that the companies plan to partner on the research of novel humanized bispecific antibodies through the exploitation of Novimmune’s kappa-lambda bispecific antibody technology platform.
According to Novimmune CEO Jack Barbut, bispecific antibodies currently used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments, or forced engineering-and Novimmune's platform is unique in that it would allow antibodies to assemble naturally, he said in a press release. Natural assembly, rather than the use of foreign sequences, could lead to enhanced product stability, better product half-life, and could also be associated with lower immunogenicity risk, noted the release.
Once developed, the final product would be an unmodified fully human bispecific immunoglobulin G (IgG). Novimmune says it has mechanisms in place for the expression of kappa-lambda-bodies in mammalian cells, and also has a purification platform that is “easily scalable and transferrable,” according to the company’s website.
Source: Novimmune
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
